Triumvira Immunologics to Present Two Posters Covering Ongoing Phase 1/2 Solid Tumor Trial and New Preclinical Gastric Cancer Data at AACR Annual Meeting 2022

April 10, 2022

Triumvira to initiate enrollment of second cohort in ongoing Phase 1/2 trial of TAC01-HER2 following data safety monitoring committee’s successful review of safety data from first cohort

AUSTIN, Texas, and HAMILTON, Ontario, April 10, 2022 – Triumvira Immunologics (“Triumvira”), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced it will present two posters at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 8-13, 2022 in New Orleans. The company will present an update from its ongoing TACTIC-2 clinical trial evaluating TAC01-HER2 in patients with HER2-positive solid tumors and new preclinical proof-of-concept data for its gastric cancer candidate, TAC-Claudin 18.2 (CLDN18.2).

“We plan to build on this success through an eventual IND filing for CLDN18.2 and look forward to expanding our novel platform to address additional targets.”